Logo for Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited Investor Relations Material

Latest events

Logo for Neuren Pharmaceuticals Limited

Study Result

Neuren Pharmaceuticals Limited
Logo for Neuren Pharmaceuticals Limited

AGM 2024 Presentation

28 May, 2024
Logo for Neuren Pharmaceuticals Limited

Study Result

27 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Neuren Pharmaceuticals Limited

Access all reports
Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on developing new therapies for neurodevelopmental disorders, including conditions that manifest in early childhood and are characterized by impaired brain cell connections and signaling. The company has a deep expertise in the field, accumulated through extensive clinical development efforts. Neuren Pharmaceuticals has gained recognition for developing the FDA-approved treatment, DAYBUE™ (trofinetide), specifically for Rett syndrome, marking a significant advancement in the treatment of this condition. Furthermore, the company is advancing its research and development pipeline with therapies aimed at addressing a range of neurodevelopmental disorders. The company is headquartered in Melbourne, Victoria, and its shares are listed on the ASX.